Every price names its source
No sponsorships, referrals or clinic partnerships
EpiPen, insulin & Ozempic prices refreshed October 2026
Cost comparison only — not medical advice
Every price names its source
No sponsorships, referrals or clinic partnerships
EpiPen, insulin & Ozempic prices refreshed October 2026
Cost comparison only — not medical advice
← All Articles
Drug Prices

Imbruvica Price by Country: $9,319 for Medicare, €4,289 in France

The same blood-cancer tablet, ibrutinib 420 mg once a day — priced from official databases in six places.

Researched with AI assistance; every figure is checked against the primary source cited on this page before publishing. How we work →

Key Takeaways

  • $9,319 for Medicare, $14,934 list in 2023. Medicare's negotiated price for a 30-day supply has applied since January 1, 2026 — 38% below the 2023 list price, the smallest cut among the first ten negotiated drugs (CMS). CMS's price file sets $353.98 per 420 mg tablet, about $10,619 for 30 (our calculation).
  • Europe: about $4,800 to $6,250 for 30 tablets. Official prices at ECB rates: France $4,792, Switzerland $5,852, the UK $6,162, the Netherlands $6,252 (our calculation for packs of 28).
  • No US pharmacy-cost figure. The national pharmacy-price survey (NADAC, October 28, 2026) has no row for ibrutinib, as often for specialty drugs, and we could not verify a current US list price.
  • Medicare's price rises with inflation in 2027: $9,571.07 for a 30-day supply, $363.55 per 420 mg tablet (CMS price file of November 2, 2026).

Imbruvica Price by Country (November 2026)

Imbruvica 420 mg, one tablet a day, so 30 days = 30 tablets. Each country's own official price; where the official pack has 28 tablets, we convert to 30 (our calculation: pack price ÷ 28 × 30). The US Medicare figure is CMS's price per tablet × 30 (our calculation). US dollars at European Central Bank reference rates of October 30, 2026.

30 days = 30 tablets of 420 mg. US: CMS maximum fair price per tablet (price file of November 2, 2026) × 30 and 2023 list price per 30-day supply (2026 fact sheet). UK: NHS dm+d. France: BDPM official price excluding dispensing fee (November 3, 2026). Switzerland: BAG public price. Netherlands: Zorginstituut average price per pack of 30 (to November 1, 2026). Converted at ECB rates of October 30, 2026; packs of 28 scaled to 30 tablets (our calculation).
CountryOfficial price30 days in US dollarsWhat a patient typically pays
🇺🇸 United States (Medicare)$9,319 negotiated price per 30-day supply, since Jan 1, 2026; $353.98 per 420 mg tablet (CMS price file); 2023 list price $14,934$10,619 for 30 tabletsDepends on the Part D plan; out-of-pocket costs are capped each year
🇺🇸 United States (pharmacy cost)No ibrutinib row in CMS NADAC (Oct 28, 2026)——
🇬🇧 United Kingdom£4,292.40 for 28 tablets (NHS price, since July 11, 2019; hospital-only pack)$6,162Usually supplied through the hospital
🇫🇷 France€4,289.07 for 30 tablets (official price excluding dispensing fee)$4,792Fully reimbursed (100%)
🇨🇭 SwitzerlandCHF 4,494.50 for 28 tablets (public price)$5,85210% share after the annual deductible
🇦🇹 Austria€4,934.75 for 28 tablets (social-insurance price excl. VAT; effective price may be lower under a price model)$5,907€7.55 prescription fee per pack; insurer approval needed first
🇳🇱 Netherlands€5,595.93 for 30 tablets (average pharmacy price)$6,252Reimbursed under conditions; counts toward the annual deductible
🇩🇪 GermanyNo statutory price ceiling (Festbetrag) for ibrutinib—€10 co-payment per pack (10%, max. €10)

We compare prices; we do not recommend where to buy medicine. Cancer treatment decisions belong with your oncologist or haematologist.

What the Numbers Mean

The smallest Medicare discount of the first ten

Imbruvica's negotiated price is $9,319 for a 30-day supply, 38% below the 2023 list price of $14,934 — the smallest reduction among the ten drugs in the first round (CMS). CMS's price file sets $353.98 per 420 mg tablet for 2026 and $363.55 from January 1, 2027 after an inflation adjustment. Medicare Part D caps a patient's yearly out-of-pocket drug costs; the cap amount is set by CMS each year.

Europe: official prices about half of Medicare's

For 30 tablets of 420 mg, France lists €4,289.07 and the Netherlands €5,595.93; for 28 tablets the UK lists £4,292.40 and Switzerland CHF 4,494.50. Converted to 30 tablets at ECB rates that is about $4,800 to $6,250 — roughly 45% to 59% of the $10,619 that Medicare's per-tablet price adds up to (our calculation).

Germany: no price ceiling and no freely published price

Ibrutinib is not on the German statutory price-ceiling (Festbetrag) list of October 15, 2026. We found no current, freely published official pharmacy price, so we show none. Insured patients pay a 10% co-payment, capped at €10 per pack (€15 from 2027).

Frequently Asked Questions

How much does Imbruvica cost in the US compared with other countries?

Medicare has paid a negotiated $9,319 for a 30-day supply of Imbruvica since January 1, 2026; the 2023 list price was $14,934 (CMS). CMS's price file sets $353.98 per 420 mg tablet. Official prices elsewhere: €4,289.07 for 30 tablets in France, €5,595.93 in the Netherlands, £4,292.40 for 28 in the UK and CHF 4,494.50 for 28 in Switzerland — roughly $4,800 to $6,250 for 30 tablets at ECB rates.

Why is there no US pharmacy price?

The CMS survey of what pharmacies pay (NADAC, October 28, 2026) has no row for ibrutinib; specialty drugs dispensed through specialty pharmacies are often missing from it. We also could not verify a current US list price from the maker.

Is there a generic Imbruvica (ibrutinib)?

We found no generic ibrutinib in the official lists we checked (US NADAC, UK dm+d, France, Switzerland, the Netherlands).

What do patients pay?

In France Imbruvica is reimbursed at 100%. In Germany statutory insurance covers it with a 10% co-payment, capped at €10 per pack. In Switzerland insured patients pay a 10% share after their deductible. In the UK the pack is hospital-only. In the US it depends on the plan; Medicare Part D caps yearly out-of-pocket costs.

Does the Medicare price change in 2027?

Yes, slightly: CMS's price file adjusts it for inflation to $9,571.07 for a 30-day supply and $363.55 per 420 mg tablet from January 1, 2027.

Sources

  1. CMS — Negotiated prices for initial price applicability year 2026 (fact sheet): Imbruvica $9,319 negotiated price, $14,934 list price (2023), 30-day supply, 38% lower
  2. CMS — Selected drug list and maximum fair price data file (November 2, 2026): Imbruvica 420 mg 57962-0420 $353.977199 per unit in 2026, $363.551937 from January 1, 2027
  3. CMS — NADAC, as of October 28, 2026: no row for ibrutinib or Imbruvica
  4. NHS dm+d — Imbruvica 420 mg tablets, 28: NHS indicative price £4,292.40 (since July 11, 2019); hospital only
  5. Base de données publique des médicaments — Imbruvica 420 mg, 30 tablets: €4,289.07 excluding dispensing fee, 100% reimbursed (updated November 3, 2026)
  6. Federal Office of Public Health (BAG) — Spezialitätenliste: Imbruvica 420 mg, 28 tablets, public price CHF 4,494.50; cost share 10%
  7. Austrian social insurance (Dachverband) — Erstattungskodex monthly data, Nov 2026: Imbruvica 420 mg Filmtabl. €4,934.75 (price model) (social-insurance price excl. VAT; chief-physician approval (RE1))
  8. oesterreich.gv.at — prescription fee (Rezeptgebühr) €7.55 per pack since January 1, 2026
  9. Zorginstituut Nederland — Medicijnkosten.nl: Imbruvica 420 mg (EU/1/14/945/005), average price €5,595.93 per pack (updated to November 1, 2026)
  10. European Medicines Agency — Imbruvica product information: EU/1/14/945/005 = 420 mg, 30 tablets
  11. Medicare.gov — Part D costs: yearly cap on out-of-pocket drug costs
  12. BfArM / GKV-Spitzenverband — Festbetrag list as of October 15, 2026 (no entry for ibrutinib)
  13. European Central Bank — reference rates, October 30, 2026 (1 US dollar = €0.89509 = £0.74633 = CHF 0.82295)

Wellness Vision Editorial Policy

Wellness Vision does not sell medicine, recommend pharmacies or suppliers, or take payments from drug makers. Every price above comes from the official source cited; conversions and per-30-tablet figures are our own calculations, shown with their formula. This is a cost comparison, not medical advice.

You shouldn't have to go broke to feel whole.